Where is Sarepta Therapeutics headquartered?

Sarepta Therapeutics is recorded with headquarters in Cambridge, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Sarepta Therapeutics publicly traded?

Yes — Sarepta Therapeutics is listed as a public company with ticker SRPT on NYSE in SEC EDGAR-derived records.

What drugs are associated with Sarepta Therapeutics?

We link 3 drug profile(s) where Sarepta Therapeutics appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Sarepta Therapeutics sponsoring?

Sarepta Therapeutics is linked to 46 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Sarepta Therapeutics as applicant?

102 USPTO PatentsView record(s) name Sarepta Therapeutics or a normalized variant as applicant.

What pipeline phases does Sarepta Therapeutics have in our database?

Phase distribution from linked programs: phase 2: 18, phase 1: 14, phase 3: 12, approved: 2.

How many US-approved drugs are linked to Sarepta Therapeutics?

3 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Sarepta Therapeutics hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Sarepta Therapeutics?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Sarepta Therapeutics data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Sarepta Therapeutics Pharmaceuticals Company Profile

Name: Sarepta Therapeutics intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 215 First Street, Cambridge, MA 02142, US
Employees: 1,150
Programs: 46
Drugs: 23
Patents: 102

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Sarepta Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SRPT. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duchenne Muscular Dystrophy (DMD), Marburg Hemorrhagic Fever, Ebola Hemorrhagic Fever. NovaPharmaNews links 46 clinical program(s), 3 drug profile(s), and 102 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (18), phase 1 (14), phase 3 (12).

Company snapshot

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. For information on our Community Guidelines, please visit sarepta.com/community-guidelines. We want to share a reminder with all job seekers and candidates regarding the persistence

4 approved product(s) across US/EU regulatory metadata.
46 active pipeline program(s) linked via ClinicalTrials.gov.
102 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Sarepta Therapeutics. Not investment advice.

Top assets

View drugs (23) View projects (46)

Lead pipeline drugs

abacavir, dolutegravir, lamivudine
approved
acyclovir sodium
approved
casimersen
approved
chloride
Marketed / approved

Active clinical programs

4045-301 Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
Phase 3
Casimersen Duchenne Muscular Dystrophy
Phase 3
Delandistrogene moxeparvovec-rokl Duchenne Muscular Dystrophy
Phase 3
ETEPLIRSEN (AVI-4658) Duchenne Muscular Dystrophy
Phase 3

Momentum

Proprietary activity score for Sarepta Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 51 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

ITALFARMACO S.P.A

TA overlap score 21.4
Peer + 0 momentum

Entrada Therapeutics

TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Sarepta Therapeutics.

Jun 8, 2026 Clinical update
ARODM1-1001 — Phase 2
Jun 8, 2026 Clinical update
SRP-9003-301 — Phase 3
Jun 8, 2026 Clinical update
SRP-9001-303 — Phase 3
Jun 8, 2026 Clinical update
SRP-9001-104 — Phase 1
Jun 8, 2026 Clinical update
4045-301 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Sarepta Therapeutics?

Sarepta Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SRPT. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duchenne Muscular Dystrophy (DMD), Marburg Hemorrhagic Fever, Ebo
Is Sarepta Therapeutics publicly traded?

Yes. Sarepta Therapeutics is listed with ticker SRPT on NYSE per SEC EDGAR records linked on this profile.
What drugs does Sarepta Therapeutics develop or market?

We link 23 drug profile(s) where Sarepta Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sarepta-therapeutics#company-drugs.
What are the latest developments for Sarepta Therapeutics?

In the last 12 months our linked public records show 46 trial program update(s) and 2 US patent grant(s) tied to this profile.
What therapeutic areas does Sarepta Therapeutics focus on?

Sarepta Therapeutics focuses on Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duchenne Muscular Dystrophy (DMD) based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Infectious Disease

Cardiology

Oncology